Answers are grounded in this paper and cite their sources.
Nutritional indices have been reported as predictors of therapeutic efficacy in Atezolizumab + Bevacizumab combination therapy (Atezo + Bev therapy) for unresectable hepatocellular carcinoma; however, the number of such reports is limited. Therefore, we investigated whether each nutritional index could be a predictor of therapeutic efficacy and compared their usefulness. The relationship between therapeutic efficacy and changes in nutritional indices was also examined. A total of 62 patients with unresectable hepatocellular carcinoma who initially received Atezo + Bev therapy were divided into a stable disease (SD) or greater group (40 patients) and a progressive disease (PD) group (22 patients); nutritional indices at the start of the treatment were compared. For nutritional indices that showed significant differences (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], prognostic nutritional index [PNI], and cholesterol-modified prognostic nutritional index [CPNI]), cutoff values (NLR: 2.3, PLR: 118.2, PNI: 41.0, and CPNI: 86.9), predictive ability, and area under the curve (AUC) were calculated. As a result, PLR and CPNI demonstrated the highest accuracy of 75.8%, with an AUC of 0.71. Patients were classified into two groups using the cutoff values of PLR and CPNI, and the progression-free survival (PFS) and overall survival (OS) were compared. The PFS and OS were significantly longer in the group with a good nutritional status. Changes in PLR and CPNI between the start of the treatment and the time of PD assessment were compared for 22 patients in the SD or better group who developed PD during the observation period; however, no significant changes were observed.
No takes yet. Share an insight, caveat, or question.
Suto et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: